CDK4 and breast cancer: In accordance with the potential of Rb as a biomarker to predict primary response to CDK4/6i, a signature of Rb loss of function (Rbsig) developed using The Cancer Genome Atlas (TCGA) dataset was able to discriminate the palbociclib-resistant BC cell lines from the sensitive ones [120,121].